Cargando…

Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials

OBJECTIVE: To compare the efficacy and safety between denosumab and zoledronic acid for advanced cancer with bone metastasis. METHODS: MEDLINE, EMBASE, and the Cochrane library databases were searched for randomized controlled trials up to December 2020 that compared denosumab and zoledronic acid in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Lianghai, Cui, Xianghua, Ma, Haoning, Tang, Xiangsheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218501/ https://www.ncbi.nlm.nih.gov/pubmed/34158101 http://dx.doi.org/10.1186/s13018-021-02554-8

Ejemplares similares

Insufficient Mitigation of Bone Loss by Zoledronic Acid after Treatment with Denosumab
por: Park, Jung-Wee
Publicado: (2021)

Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial
por: Raje, N, et al.
Publicado: (2016)

Comparison of Denosumab and Zoledronic Acid in Postmenopausal Women With Osteoporosis: Bone Mineral Density (BMD) and Trabecular Bone Score (TBS)
por: Kang, Taewook, et al.
Publicado: (2022)

Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study
por: Nasser, Sahar M, et al.
Publicado: (2019)

Clinical Efficacy and Safety of Zoledronic Acid Combined with PVP/PKP in the Treatment of Osteoporotic Vertebral Compression Fracture: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Sun, Yan, et al.
Publicado: (2021)

Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab
por: Yamasaki, Mutsushi, et al.
Publicado: (2016)

Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year
por: Kadaru, Tarun, et al.
Publicado: (2021)

Comparison of denosumab and oral bisphosphonates for the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
por: Jiang, Lianghai, et al.
Publicado: (2022)

Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study—Asian Subgroup Analysis
por: Huang, Shang-Yi, et al.
Publicado: (2020)

OR13-02 Treatment with Zoledronic Acid Subsequent to Denosumab Cannot Fully Prevent Bone Loss
por: Sølling, Anne Sophie K, et al.
Publicado: (2020)

Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patients
por: Makras, Polyzois, et al.
Publicado: (2021)

The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials
por: Zhang, Zhicai, et al.
Publicado: (2017)

Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022)

Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study
por: Tutaworn, Teerapat, et al.
Publicado: (2023)

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
por: Rader, Michael, et al.
Publicado: (2012)

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
por: Xie, Jipan, et al.
Publicado: (2011)

Zoledronic Acid Versus Denosumab for Prevention of Spinal Cord Compression in Advanced Cancers With Spine Metastasis: A Meta-Analysis of Randomized Controlled Trials
por: Al Farii, Humaid, et al.
Publicado: (2019)

Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology
por: Fusco, Vittorio, et al.
Publicado: (2018)

In Silico Investigations of the Anti-Catabolic Effects of Pamidronate and Denosumab on Multiple Myeloma-Induced Bone Disease
por: Wang, Yan, et al.
Publicado: (2012)

The Effect of Zoledronic Acid on Bone Microarchitecture and Strength after Denosumab and Teriparatide Administration: DATA‐HD Study Extension
por: Ramchand, Sabashini K., et al.
Publicado: (2022)

Giant cell tumour of bone in os sacrum of a prepubertal girl – Surgical and medical treatment with zoledronate and denosumab
por: Beck-Nielsen, Signe Sparre, et al.
Publicado: (2023)

The Role of Denosumab for Surgical Outcomes in Patients with Giant Cell Tumour of Bone: A Systematic Review
por: Gupta, Abha, et al.
Publicado: (2021)

PB1981: EFFICACY AND SAFETY OF DENOSUMAB IN PATIENTS WITH MULTIPLE MYELOMA
por: Bougherira, S., et al.
Publicado: (2022)

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
por: Miller, P. D., et al.
Publicado: (2016)

Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteoporosis
por: Yassin, Mohamed A., et al.
Publicado: (2020)

Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study
por: Everts-Graber, Judith, et al.
Publicado: (2023)

Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial
por: Li, Shenglong, et al.
Publicado: (2019)

Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases
por: Ikesue, Hiroaki, et al.
Publicado: (2021)

Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases
por: Ikesue, Hiroaki, et al.
Publicado: (2021)

Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial
por: Yue, Jiaji, et al.
Publicado: (2022)

A Multi-Institutional Randomized Controlled Trial to Investigate Whether Zoledronate Prevents Bone Loss After Discontinuation of Denosumab: The Study Protocol of Denosumab Sequential Therapy (DST) Trial
por: Lee, Chia-Che, et al.
Publicado: (2021)

Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis
por: Nakamura, Yumejiro, et al.
Publicado: (2021)

Denosumab/ibandronic acid/zoledronic acid: Medication-related osteonecrosis of jaw: case report
Publicado: (2021)

Effect of Denosumab on the Change of Osteoclast Precursors Compared to Zoledronate Treatment in Postmenopausal Women with Osteoporosis
por: Kong, Sung Hye, et al.
Publicado: (2022)

Correction to: Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study
por: Everts-Graber, Judith, et al.
Publicado: (2023)

Reply to Comment—Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology
por: Raje, Noopur, et al.
Publicado: (2019)

A systematic review and meta-analysis of interventional studies of bisphosphonates and denosumab in multiple myeloma and future perspectives
por: Chatziravdeli, Vasiliki, et al.
Publicado: (2022)

Denosumab Therapy for Giant Cell Tumor of Bone Pulmonary Metastasis
por: Egbert, Ryan Carlisle, et al.
Publicado: (2017)

Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan
por: Mori, Takahiro, et al.
Publicado: (2021)

Management of bone metastasis with zoledronic acid: A systematic review and Bayesian network meta-analysis
por: Lorange, Justin-Pierre, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l1fgm096lnkk2f8pjvs1chm11v